MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

For the year ending 2025-12-31.

Income Overview

Net Income
-$103,415K
EPS
-$1.83
Unit: Thousand (K) dollars

Income Statement
2025-12-31
Research and development
85,856
General and administrative
33,802
Total operating expenses
119,658
Loss from operations
-119,658
Interest income
16,013
Change in fair value of contingent value right liability
0
Income tax expense
0
Other expense
-49
Total other income (expense), net
15,964
Net loss
-103,694
Net unrealized gains (losses) on marketable securities
279
Comprehensive loss
-103,415
Basic EPS
-1.83
Diluted EPS
-1.83
Basic Average Shares
56,664,226
Diluted Average Shares
56,664,226
Unit: Thousand (K) dollars (except for numbers of shares and EPS).

Time Plot

Show the time plot by selecting a row from the table.

Income Statement

DownloadDownload image
Comprehensive loss-$103,415K Net unrealizedgains (losses) on...$279K Interest income$16,013K Net loss-$103,694K Total other income(expense), net$15,964K Other expense-$49K Loss from operations-$119,658K Total operatingexpenses$119,658K Research and development$85,856K General andadministrative$33,802K

Enliven Therapeutics, Inc. (ELVN)

Enliven Therapeutics, Inc. (ELVN)